AUA 2021 - American Urological Association Annual Meeting (Virtual Meeting)
Sep 10 - Sep 13, 2021 | Las VegasNVUS
LARVOL is not affiliated with American Urological Association Annual Meeting (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 81 abstracts linked to Trials
[VIRTUAL] Relevance of Alternative Anti-Androgen Therapy for Castration-Resistant Prostate Cancer After Combined Androgen Blockade: A Prospective Observational Study of OCCU-CRPC Cohort
[VIRTUAL] Pembrolizumab (Pembro) Plus Olaparib in Patients With Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer (mCRPC): Updated Results From KEYNOTE-365 Cohort A With a Minimum of 11 Months of Follow-Up for All Patients
[VIRTUAL] Avelumab first-line maintenance for advanced urothelial carcinoma: analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial
[VIRTUAL] Prostate-Specific Antigen Kinetics in Patients With Advanced Prostate Cancer Treated With Apalutamide: Results from the TITAN and SPARTAN Studies
[VIRTUAL] Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer Patients Who Received Prior Antiandrogen Therapy: Post Hoc Analysis of ARCHES
[VIRTUAL] Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: transcriptomic data from patients receiving placebo on a randomized phase 3 trial (PROTECT)
[VIRTUAL] Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: analysis of 18F-DCFPyL uptake in possible extra-pelvic oligometastases
[VIRTUAL] Phase III Trial of Intravesical Nadofaragene Firadenovec in Patients with High-Grade, BCG-Unresponsive, Non-muscle Invasive Bladder Cancer: Two Year Follow-up in the Ta/T1 Cohort
[VIRTUAL] Efficacy of physician's choice of enzalutamide or abiraterone in the control arm of PROfound
[VIRTUAL] Impact of darolutamide on local symptoms in patients with nonmetastatic castration-resistant prostate cancer
[VIRTUAL] Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance: ENACT
[VIRTUAL] NAXIVA - A phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer with venous invasion: Translational results
[VIRTUAL] Anti-adenoviral Antibody Levels Predict Nadofaragene Firadenovec Response in BCG-unresponsive NMIBC: Results from a Phase 3 Trial
[VIRTUAL] Phase 2/3 clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ (CIS) patients.
[VIRTUAL] Estimating recurrence-free survival of non-muscle invasive bladder cancer after intravesical therapy: A clinical-based recursive partition analysis